Neurelis Inc.

Jun 08, 2020

Neurelis Announces Rapid and Broad Payer Coverage of the Company's Flagship Product, VALTOCO® (Diazepam Nasal Spray)

May 20, 2020

Neurelis Announces Total Of Nine Poster Presentations For The AANN, AMCP, And AAN Annual Meetings

May 04, 2020

Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals' Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure To Epinephrine Injectors

Mar 02, 2020

Neurelis Announces Commercial Availability of VALTOCO® (Diazepam Nasal Spray) for Seizure Cluster Rescue

Jan 13, 2020

Neurelis Announces FDA Approval for Seizure Rescue Treatment VALTOCO® (Diazepam Nasal Spray) that Incorporates the Science of Intravail® for Consistent and Reliable Absorption

Dec 05, 2019

Neurelis Announces Nine Poster Presentations At The Annual Meeting Of The American Epilepsy Society

Oct 22, 2019

Neurelis Announces Three Poster Presentations At The Annual Meeting Of The Child Neurology Society

Apr 29, 2019

Neurelis Announces Two Poster Presentations At The Annual Meeting Of The American Academy Of Neurology

Apr 22, 2019

Neurelis Announces Completion Of Senior Management Team Buildout To Support The Anticipated Commercial Launch Of VALTOCO(TM)

Nov 07, 2017

Neurelis Expands Worldwide Patent Portfolio With Latest Issuance In Japan